Reteplase for dysfunctional hemodialysis catheter clearance

Pharmacotherapy

Volumn 23, Issue 2, 2003, Pages 137-141

  Hilleman, Daniel E ^a   Dunlay, Robert W ^b   Packard, Kathleen A ^c  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; RETEPLASE;

ADULT; AGED; ARTICLE; ASPIRATION; BLEEDING; BLOOD FLOW VELOCITY; CATHETER DYSFUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INSTILLATION; FEMALE; HEALTH CARE COST; HEMODIALYSIS; HUMAN; INTRAVENOUS CATHETER; KIDNEY FAILURE; MALE; OBSTRUCTION; OPEN STUDY; RECANALIZATION; SIDE EFFECT; VASCULAR ACCESS; VENOUS PRESSURE;

CATHETERS, INDWELLING; DISEASE-FREE SURVIVAL; EQUIPMENT FAILURE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RENAL DIALYSIS; THROMBOLYTIC THERAPY; THROMBOSIS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR PATENCY;

EID: 0037318513     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.2.137.32086     Document Type: Article

References (24)

1. United States Renal Data System. 2001 annual data report: atlas of end stage renal disease in the United States - incidence and prevalence. Am J Kidney Dis 2001;38(suppl 3):537-52.
2. Arnold WP. Improvement in hemodialysis vascular access outcomes in a dedicated access center. Semin Dial 2000; 13:359-63.
3. National Kidney Foundation-Dialysis Outcomes Quality Initiative. NKF-DOQ1 clinical practice guidelines. Update 2000. Am J Kidney Dis 2001;37(suppl 1):S1-238.
4. Miller PE, Carlton D, Dejerhoi MH, Redden DT, Allon M. Natural history of arteriovenous grafts in hemodialysis patients. Am J Kidney Dis 2000;36:68-74.
5. Allon M, Ornt DB, Schwab SJ, et al. Factors associated with the prevalence of arteriovenous fistulas in hemodialysis patients in the HEMO study. Kidney Int 2000;58:2178-85.
6. Boyle MJ, Gawley WF, Hickey DP, et al. Experience using the Quinton Permcath for hemodialysis in the Irish Republic. Nephrol Dial Transplant 1997;12:1934-99.
7. Schnabel KJ, Simons ME, Zevallos GF, et al. Image-guided insertion of the Uldall tunneled hemodialysis catheter: technical success and clinical follow-up. J Vasc Interv Radiol 1997;8:579-86.
8. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Clinical practice guidelines for vascular access. Am J Kidney Dis 1997;30:S152-89.
9. Paulsen D, Reisoether A, Aaren M, Fauchald P. Use of tissue plasminogen activator for reopening clotted dialysis catheters. Nephron 1993;64:468-70.
10. Schenk P, Rosenkranz AR, Wolfi G, Hori WH, Traindl O. Recombinant tissue plasminogen activator is a useful alternative to heparin in priming Quinton Permcath. Am J Kidney Dis 2000;35:130-6.
11. Spry LA, Miller G. Low-dose tPA for hemodialysis catheter clearance. Dialysis Transplant 2001;30:10-12.
12. Savader SJ, Ehrman KO, Porta DJ, Haikal LC, Oteham AC. Treatment of hemodialysis catheter-associated fibrin sheaths by rt-PA infusion: critical analysis of 124 procedures. J Vasc Interv Radiol 2001;12:711-15.
13. Daeihagh P, Jordan J, Chen J, Rocco M. Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters. Am J Kidney Dis 2000;36:75-9.
14. Crowther MA, Stevens L, Ingram A, et al. Effectiveness of reconstituted and then frozen t-PA for dysfunctional percutaneous dialysis catheters [abstr]. Blood 2000;96(2 pt 2):4080.
15. Dowling K, Sansivero G, Stainken B, et al. The use of tissue plasminogen activator infusion to re-establish function of tunnelled hemodialysis catheters [abstr]. Vasc Interv Radiol 2000;11(2 pt 2):86.
16. Twardowski ZJ. High-dose intradialytic urokinase to restore patency of permanent central vein hemodialysis catheters. Am J Kidney Dis 1998;31:841-67.
17. Seddon PA, Hrinya MK, Gaynord MA, Lion CM, Mangold BM, Bruns FJ. Effectiveness of low-dose urokinase on dialysis catheter thrombolysis. ASAIO J 1998;44:559-61.
18. Northsea C. Using urokinase to restore patency in double lumen catheters. Am Nephrol Nurses Assoc J 1994;21:261-4.
19. Haire WD, Leiberman RP, Lund GB, et al. Obstructed central venous catheter: restoring function with a 12 hour infusion of low-dose urokinase. Cancer 1990;66:2279-85.
20. Semba CP, Bakal CW, Calis KA, et al. Alteplase as an alternative to urokinase. J Vasc Interv Radiol 2000;11:279-87.
21. Stephens MB, Petter PV. Streptokinase therapy. Recognizing and treating allergic reactions. Postgrad Med 1998;103: 89-90.
22. Castner D. The efficacy of reteplase in the treatment of thrombosed hemodialysis venous catheters. Nephrol Nurs J 2001;28:403-19.
23. Medi-Span. Price-Chek PC, version 2.16. St. Louis: Medi-Span, 2002.
24. Centocor, Inc. Data on file. Malvern, PA;2000.